Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- PMID: 23999198
- PMCID: PMC4052428
- DOI: 10.1038/ijo.2013.162
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
Abstract
Introduction: Mechanisms for liraglutide-induced weight loss are poorly understood.
Objective: We investigated the effects of liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese non-diabetic individuals.
Design: Participants (N=49, 18-75 years, body mass index: 30-40 kg m(-2)) were randomized to two of three treatments: liraglutide 1.8 mg, 3.0 mg, or placebo in a double-blind, incomplete crossover trial. After 5 weeks, 24-h energy expenditure (EE) and substrate oxidation were measured in a respiratory chamber. Gastric emptying (acetaminophen absorption method), glycemic parameters and appetite were assessed during a 5-h meal test. Ad libitum energy intake during a subsequent lunch was also assessed.
Results: Five-hour gastric emptying (AUC(0-300 min)) was found to be equivalent for liraglutide 1.8 versus 3.0 mg (primary end point), and for both liraglutide doses versus placebo, as 90% confidence intervals for the estimated treatment ratios were contained within the prespecified interval (0.80-1.25). However, 1-h gastric emptying was 23% lower than placebo with liraglutide 3.0 mg (P=0.007), and a nonsignificant 13% lower than placebo with liraglutide 1.8 mg (P=0.14). Both liraglutide doses similarly reduced fasting glucose (0.5-0.6 mmol l(-1) versus placebo, P<0.0001), glucose Cmax and 1-h AUC versus placebo; only liraglutide 3.0 mg reduced iAUC(0-300 min) (by ∼26% versus placebo, P=0.02). Glucagon iAUC(0-300 min) decreased by ∼30%, and iAUC(0-60 min) for insulin and C-peptide was ∼20% lower with both liraglutide doses versus placebo. Liraglutide doses similarly increased mean postprandial satiety and fullness ratings, reduced hunger and prospective food consumption and decreased ad libitum energy intake by ∼16%. Liraglutide-associated reductions in EE were partly explained by a decrease in body weight. A relative shift toward increased fat and reduced carbohydrate oxidation was observed with liraglutide. Clinicaltrials.gov ID:NCT00978393.
Funding: Novo Nordisk.
Conclusion: Gastric emptying AUC(0-300 min) was equivalent for liraglutide 1.8 and 3.0 mg, and for liraglutide versus placebo, whereas reductions in 1-h gastric emptying of 23% with liraglutide 3.0 mg and 13% with 1.8 mg versus placebo were observed. Liraglutide 3.0 mg improved postprandial glycemia to a greater extent than liraglutide 1.8 mg. Liraglutide-induced weight loss appears to be mediated by reduced appetite and energy intake rather than increased EE.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4052428/bin/ijo2013162f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4052428/bin/ijo2013162f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4052428/bin/ijo2013162f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4052428/bin/ijo2013162f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4052428/bin/ijo2013162f5.gif)
Similar articles
-
Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.Diabetes Res Clin Pract. 2012 Aug;97(2):258-66. doi: 10.1016/j.diabres.2012.02.016. Epub 2012 Mar 24. Diabetes Res Clin Pract. 2012. PMID: 22446097 Clinical Trial.
-
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.Lancet Gastroenterol Hepatol. 2017 Dec;2(12):890-899. doi: 10.1016/S2468-1253(17)30285-6. Epub 2017 Sep 27. Lancet Gastroenterol Hepatol. 2017. PMID: 28958851 Clinical Trial.
-
The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.Diabetes Obes Metab. 2013 Oct;15(10):958-62. doi: 10.1111/dom.12108. Epub 2013 Apr 23. Diabetes Obes Metab. 2013. PMID: 23551925 Clinical Trial.
-
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.Adv Exp Med Biol. 2021;1307:171-192. doi: 10.1007/5584_2020_496. Adv Exp Med Biol. 2021. PMID: 32077010 Review.
-
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Diabetes Obes Metab. 2013. PMID: 22985213 Review.
Cited by
-
A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity.J Obes. 2024 May 10;2024:8056440. doi: 10.1155/2024/8056440. eCollection 2024. J Obes. 2024. PMID: 38765635 Free PMC article. Review.
-
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.Endocrinol Metab (Seoul). 2024 Apr;39(2):206-221. doi: 10.3803/EnM.2024.1940. Epub 2024 Apr 16. Endocrinol Metab (Seoul). 2024. PMID: 38626909 Free PMC article. Review.
-
Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.Drug Des Devel Ther. 2024 Mar 18;18:845-858. doi: 10.2147/DDDT.S445415. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38524878 Free PMC article.
-
Molecular Mechanisms in the Etiology of Polycystic Ovary Syndrome (PCOS): A Multifaceted Hypothesis Towards the Disease with Potential Therapeutics.Indian J Clin Biochem. 2024 Jan;39(1):18-36. doi: 10.1007/s12291-023-01130-7. Epub 2023 Mar 18. Indian J Clin Biochem. 2024. PMID: 38223007 Review.
-
Role of Liraglutide Use in Patients With Heart Failure.Cureus. 2023 Dec 6;15(12):e50065. doi: 10.7759/cureus.50065. eCollection 2023 Dec. Cureus. 2023. PMID: 38186489 Free PMC article. Review.
References
-
- Kopelman PG. Obesity as a medical problem. Nature. 2000;404:635–643. - PubMed
-
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79. - PubMed
-
- Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197–1211. - PubMed
-
- Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452–458. - PubMed
-
- Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38:665–673. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical